Mesoblast Limited (NASDAQ: MESO; ASX: MSB) acquired an exclusive worldwide license to a chimeric antigen receptor (CAR) technology platform for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Mergers and Acquisitions